This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD)	Monoacylglycerol lipase (MAGL)	Mouse studies suggest inhibiting MAGL may help treat PD by reducing neuroinflammation. In a mouse model of neuroinflammation, Magl deficiency or a MAGL inhibitor lowered inflammatory prostaglandin and cytokine levels in the brain compared with wild-type Magl expression or vehicle. In a mouse model of PD, a MAGL inhibitor prevented dopaminergic neurodegeneration compared with vehicle. Next steps include evaluating MAGL inhibition in additional models of PD. *SciBX* 4(44); doi:10.1038/scibx.2011.1244 Published online Nov. 10, 2011	Patented; licensing status undisclosed	Nomura, D.K. *et al. Science*; published online Oct. 20, 2011; doi:10.1126/science.1209200 **Contact:** Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, Calif. e-mail: cravatt@scripps.edu **Contact:** Daniel K. Nomura, University of California, Berkeley, Calif. e-mail: dnomura@berkeley.edu